文献速递妇科

原发人乳头瘤病毒检测与宫颈癌筛查的其他新技术

Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening.
PubMed 文献 · Obstet Gynecol · 2023-09-13

本文综述宫颈癌筛查从细胞学向原发人乳头瘤病毒(HPV)检测转变的进展,指出稳健的前瞻性队列数据支持精确风险分层,p16/Ki-67双染和HPV甲基化panel等新技术性能与联合检测相当,美国自我采样可减少筛查障碍,但实施面临工作流程、人力和成本问题。

要点

  • 筛查正从宫颈细胞学转向原发HPV检测,前瞻性队列数据支持精确风险分层。
  • p16/Ki-67双染和HPV甲基化panel性能与联合检测相当,可发展为全分子Pap检测。
  • 美国自我采样结合新技术或可减少常规筛查障碍,但需解决工作流程、人力和成本问题。

核心结论

  • 原发HPV检测及p16/Ki-67双染、HPV甲基化panel等新技术可改善风险分层并减少不必要的诊断操作,但实施需解决工作流程、人力和成本障碍,以实现更公平的筛查。

研究设计与样本

  • 综述,总结原发HPV检测、p16/Ki-67双染、HPV甲基化panel及自我采样等新技术的现有证据。

主要发现

  • 原发HPV检测的前瞻性队列数据支持精确风险分层,识别高级别病变并减少不必要的诊断操作。
  • p16/Ki-67双染和HPV甲基化panel性能与联合检测相当,可开发为高通量工作流程。
  • 美国自我采样可在家庭完成初筛,结合新技术或可减少常规筛查障碍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cervical cancer screening has saved the lives of millions in regions where routine gynecologic care is readily accessible. As screening continues to evolve away from cervical cytology to primary human papillomavirus (HPV) testing, robust prospective cohort data have allowed for precise risk stratification and improved our ability to identify those at greatest risk of high-grade dysplasia and decrease unnecessary diagnostic procedures. New technologies such as p16/Ki-67 dual stain testing and HPV methylation panels, which offer comparable performance to co-testing and can be developed into high-throughput workflows, could lead to a fully molecular Pap test. Self-sampling in the United States, where the initial screen can be done in the home, in conjunction with new screening technologies, may decrease the existing hurdles of routine cervical cancer screening. Implementation barriers include issues with workflow, workforce, and cost. These need to be addressed to achieve an improved and more equitable cervical cancer screening program in the United States.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Einstein MH, Zhou N, Gabor L, et al. Primary Human Papillomavirus Testing and Other New Technologies for Cervical Cancer Screening. Obstet Gynecol. 2023. PMID: 37708516. doi:10.1097/AOG.0000000000005393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。